Pub Date : 2023-06-27DOI: 10.20471/lo.2023.51.01.01
S. Ramić, M. Perić-Balja, Ita Hadžisejić, Z. Marušić, V. Blažičević, S. Tomić
Aim: Activating somatic mutations in p110α catalytic subunit of PIK3-kinase (PIK3CA) are present in about 40% of breast cancers (BC), and are involved in oncogenesis and cancer growth. PIK3CA inhibitor therapy is approved for patients with advanced HR+/HER2- endocrine-resistant BC with somatic PIK3CA mutations. Such targeted therapy improved patient disease-free survival. Method: Analyses of PIK3CA gene mutations were performed in five University Hospital Centers in Croatia. Qualitative detection of PIK3CA gene mutations was performed on DNA extracted from 507 breast cancer samples, by the real-time PCR method using Cobas® PIK3CA mutation test. Results: PIK3CA gene mutations were detected in 209 (42.2%) out of 495 successfully analyzed cases. In 12 cases (2.4%), the tumor tissue was not of sufficient quality for analysis. Most mutations were detected in the helical (41.2%) and kinase domains (46.9%) of the PIK3CA protein. The most frequently detected mutations were H1047L/R/Y (46.4%), E545A/D/G/K (26.3%) and E542K (13.9%), followed by N345K (8.1%). PIK3CA mutations were detected in 44.8% of primary BC cases and in 39.6% of metastatic lesions (χ2=0.647; P=0.421). The age of the tissue did not significantly affect the percentage of detected mutations (χ2=0.543; P =0.461). Institutions differed in the number of analyzed cases, but not in the percentage of detected PIK3CA mutations (χ2=6.23; df=4; P=0.183) nor in the frequency of the most common mutations (χ2=2.65; df=4; P=0.618). Conclusion: The frequencies of PIK3CA mutations correspond to those reported in the literature. We have shown that the tissue of primary BC as well as metastatic lesions are suitable for analysis, and that the age of the tissue is not a significant obstacle in the analysis.
{"title":"Results of multicenter testing of PIK3CA somatic mutations in hormone-receptor positive HER2-negative advanced breast cancer","authors":"S. Ramić, M. Perić-Balja, Ita Hadžisejić, Z. Marušić, V. Blažičević, S. Tomić","doi":"10.20471/lo.2023.51.01.01","DOIUrl":"https://doi.org/10.20471/lo.2023.51.01.01","url":null,"abstract":"Aim: Activating somatic mutations in p110α catalytic subunit of PIK3-kinase (PIK3CA) are present in about 40% of breast cancers (BC), and are involved in oncogenesis and cancer growth. PIK3CA inhibitor therapy is approved for patients with advanced HR+/HER2- endocrine-resistant BC with somatic PIK3CA mutations. Such targeted therapy improved patient disease-free survival. Method: Analyses of PIK3CA gene mutations were performed in five University Hospital Centers in Croatia. Qualitative detection of PIK3CA gene mutations was performed on DNA extracted from 507 breast cancer samples, by the real-time PCR method using Cobas® PIK3CA mutation test. Results: PIK3CA gene mutations were detected in 209 (42.2%) out of 495 successfully analyzed cases. In 12 cases (2.4%), the tumor tissue was not of sufficient quality for analysis. Most mutations were detected in the helical (41.2%) and kinase domains (46.9%) of the PIK3CA protein. The most frequently detected mutations were H1047L/R/Y (46.4%), E545A/D/G/K (26.3%) and E542K (13.9%), followed by N345K (8.1%). PIK3CA mutations were detected in 44.8% of primary BC cases and in 39.6% of metastatic lesions (χ2=0.647; P=0.421). The age of the tissue did not significantly affect the percentage of detected mutations (χ2=0.543; P =0.461). Institutions differed in the number of analyzed cases, but not in the percentage of detected PIK3CA mutations (χ2=6.23; df=4; P=0.183) nor in the frequency of the most common mutations (χ2=2.65; df=4; P=0.618). Conclusion: The frequencies of PIK3CA mutations correspond to those reported in the literature. We have shown that the tissue of primary BC as well as metastatic lesions are suitable for analysis, and that the age of the tissue is not a significant obstacle in the analysis.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41333247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-27DOI: 10.20471/lo.2023.51.01.06
S. Doko, B. Stubljar, Marija Pastorčić-Grgić
After an extensive tumor resection, a defect of the floor of the mouth is a significant reconstructive challenge. The main goal is to preserve the mobility of the tongue, which allows the restauration of mastication, deglutition, and articulation. Today, a standard method for reconstruction of floor of the mouth defects is free microvascular flaps, especially radial forearm free flap. Despite that, a potential problem is the high perioperative risk and high complication rate associated with the patient’s age and comorbidities. Current literature suggests that a local nasolabial flap is a reliable treatment option for reconstruction of this type of defect, with a low complication rate and excellent functional and aesthetic results. The aim of this case presentation is to show the use of a local nasolabial flap for reconstruction of the floor of the mouth and to determine the criteria for this type of reconstruction. We present a patient who underwent resection of a floor of the mouth tumor. Due to the patient’s age, medical condition, and comorbidities, the defect was reconstructed with a local nasolabial flap. There were no postoperative complications. Articulation, mastication, and deglutition were satisfactorily rehabilitated. Follow-up showed no signs of recurrent disease twelve months postoperatively. To conclude, a local nasolabial flap is still an important reconstructive choice for oral cavity defects, especially for elderly patients with multiple comorbidities who have a higher risk of perioperative complications.
{"title":"Use of nasolabial flap for reconstruction of the floor of the mouth defects","authors":"S. Doko, B. Stubljar, Marija Pastorčić-Grgić","doi":"10.20471/lo.2023.51.01.06","DOIUrl":"https://doi.org/10.20471/lo.2023.51.01.06","url":null,"abstract":"After an extensive tumor resection, a defect of the floor of the mouth is a significant reconstructive challenge. The main goal is to preserve the mobility of the tongue, which allows the restauration of mastication, deglutition, and articulation. Today, a standard method for reconstruction of floor of the mouth defects is free microvascular flaps, especially radial forearm free flap. Despite that, a potential problem is the high perioperative risk and high complication rate associated with the patient’s age and comorbidities. Current literature suggests that a local nasolabial flap is a reliable treatment option for reconstruction of this type of defect, with a low complication rate and excellent functional and aesthetic results. The aim of this case presentation is to show the use of a local nasolabial flap for reconstruction of the floor of the mouth and to determine the criteria for this type of reconstruction. We present a patient who underwent resection of a floor of the mouth tumor. Due to the patient’s age, medical condition, and comorbidities, the defect was reconstructed with a local nasolabial flap. There were no postoperative complications. Articulation, mastication, and deglutition were satisfactorily rehabilitated. Follow-up showed no signs of recurrent disease twelve months postoperatively. To conclude, a local nasolabial flap is still an important reconstructive choice for oral cavity defects, especially for elderly patients with multiple comorbidities who have a higher risk of perioperative complications.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43514152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-27DOI: 10.20471/lo.2023.51.01.04
Tea Budija, J. Marić-Brozić
Treatment for gastric cancer has multiple approaches and options across the world. Standard treatment for the Asian population comprises D2-gastrectomy and adjuvant chemotherapy. However, in Europe and North America, clinical trials have shown that perioperative chemotherapy, given to patients before surgery, could improve resection and survival rates significantly. Most recent studies have also discussed the advantages of doublet vs. triplet chemotherapy regimens. Furthermore, researchers have been comparing the effects of perioperative chemoradiotherapy as opposed to chemotherapy alone. The specific advantages of previously stated therapy options, as well as any novel treatments, should be researched more thoroughly in the future.
{"title":"Latest perspectives on the benefits of neoadjuvant therapy for patients with advanced gastric cancer","authors":"Tea Budija, J. Marić-Brozić","doi":"10.20471/lo.2023.51.01.04","DOIUrl":"https://doi.org/10.20471/lo.2023.51.01.04","url":null,"abstract":"Treatment for gastric cancer has multiple approaches and options across the world. Standard treatment for the Asian population comprises D2-gastrectomy and adjuvant chemotherapy. However, in Europe and North America, clinical trials have shown that perioperative chemotherapy, given to patients before surgery, could improve resection and survival rates significantly. Most recent studies have also discussed the advantages of doublet vs. triplet chemotherapy regimens. Furthermore, researchers have been comparing the effects of perioperative chemoradiotherapy as opposed to chemotherapy alone. The specific advantages of previously stated therapy options, as well as any novel treatments, should be researched more thoroughly in the future.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47563838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-27DOI: 10.20471/lo.2023.51.01.03
Katarina Antunac, L. Beketić-Orešković
Traditionally, as a standard dose fractionation schedule, adjuvant radiotherapy for breast cancer has been performed using prescribed doses of 46–50 Gy divided into daily fractions of 1.8–2 Gy. Overall, radiotherapy treatment took 5 weeks. In the 1990s, schedules using higher daily doses (2.5–3 Gy), a smaller number of fractions (hypofractionation), and a reduced overall prescribed dose started in the context of clinical trials. First results revealed an equivalent cosmetic effect of hypofractionated protocols compared to standard fractionation, and after longer follow-up, hypofractionation was connected with better control of the disease. Hypofractionation started to be considered the new treatment standard. Results of newer clinical trials confirm the efficacy and safety of adjuvant breast cancer radiotherapy lasting 5 working days using daily fractions of 5.2 Gy in certain subgroups of breast cancer patients.
{"title":"Breast cancer radiotherapy - changes in fractionation schemes through decades","authors":"Katarina Antunac, L. Beketić-Orešković","doi":"10.20471/lo.2023.51.01.03","DOIUrl":"https://doi.org/10.20471/lo.2023.51.01.03","url":null,"abstract":"Traditionally, as a standard dose fractionation schedule, adjuvant radiotherapy for breast cancer has been performed using prescribed doses of 46–50 Gy divided into daily fractions of 1.8–2 Gy. Overall, radiotherapy treatment took 5 weeks. In the 1990s, schedules using higher daily doses (2.5–3 Gy), a smaller number of fractions (hypofractionation), and a reduced overall prescribed dose started in the context of clinical trials. First results revealed an equivalent cosmetic effect of hypofractionated protocols compared to standard fractionation, and after longer follow-up, hypofractionation was connected with better control of the disease. Hypofractionation started to be considered the new treatment standard. Results of newer clinical trials confirm the efficacy and safety of adjuvant breast cancer radiotherapy lasting 5 working days using daily fractions of 5.2 Gy in certain subgroups of breast cancer patients.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46448487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-27DOI: 10.20471/lo.2023.51.01.05
B. Jurić, Amir Ibukić, Slaven Čiček, Ivan Penavić, D. Tomas, A. Demirović
Appendiceal intussusception is a rare clinical entity that, in women of reproductive age, may be caused by endometriosis. We report a case of a 36-year-old woman presenting with abdominal pain. The patient underwent laparoscopic surgery, during which a suspicion of a cecal tumor was raised. A laparoscopic right hemicolectomy was performed. The patohistological exam showed an intussuscepted appendix, and the cause of the intussusception was massive endometriosis involving the colon, ileum, and appendix. It is important not to mistake appendiceal intussusception and appendiceal endometriosis with other intraabdominal pathologies whose symptoms they can mimic
{"title":"Massive endometriosis mimicking tumor – unusual cause of appendiceal intussusception","authors":"B. Jurić, Amir Ibukić, Slaven Čiček, Ivan Penavić, D. Tomas, A. Demirović","doi":"10.20471/lo.2023.51.01.05","DOIUrl":"https://doi.org/10.20471/lo.2023.51.01.05","url":null,"abstract":"Appendiceal intussusception is a rare clinical entity that, in women of reproductive age, may be caused by endometriosis. We report a case of a 36-year-old woman presenting with abdominal pain. The patient underwent laparoscopic surgery, during which a suspicion of a cecal tumor was raised. A laparoscopic right hemicolectomy was performed. The patohistological exam showed an intussuscepted appendix, and the cause of the intussusception was massive endometriosis involving the colon, ileum, and appendix. It is important not to mistake appendiceal intussusception and appendiceal endometriosis with other intraabdominal pathologies whose symptoms they can mimic","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49556275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-27DOI: 10.20471/lo.2023.51.01.02
B. Petrić-Miše, Monika Katalenić, Darijo Hrepić, S. Kuret, Irena Drmić-Hofman0000-0002-4986-9589
Aim: To investigate the clinical and pathohistological tumor characteristics, treatment, and treatment outcomes in patients with hereditary breast and ovarian cancer who were diagnosed, treated, and monitored at the University Hospital of Split from October 1999 to April 2021. Methods: The data were collected retrospectively from the medical history of 15 patients. They included the patient’s age at diagnosis, family history of malignancies, histological subtype, grade, breast cancer immunophenotype, stage of disease, status and types of BRCA mutations, type of surgical and oncological treatment, the specifics of metachronous bilateral breast cancers, the specifics of synchronous breast and ovarian cancers, and the outcome of treatment through overall survival (OS). Results: The median age of patients at the time of diagnosis of breast cancer was 53 years, and for ovarian cancer it was 56 years. A positive family history was confirmed in 13 patients (87%). All ovarian cancer patients had a high-grade serous histologic type, most often diagnosed in FIGO stages III and IV. Breast cancers were most commonly diagnosed in stages IA and IIA, with equally represented triple-negative and luminal immunophenotypes. The most common mutation was BRCA1 c.5266dup. The median OS of our patients was not reached. Conclusion: The clinical features of patients, pathohistological characteristics of tumors, and treatment outcomes in our study population are comparable with reports in the literature, respecting the specifics of different nations and race
{"title":"Hereditary breast and ovarian cancer – University Hospital of Split experiences","authors":"B. Petrić-Miše, Monika Katalenić, Darijo Hrepić, S. Kuret, Irena Drmić-Hofman0000-0002-4986-9589","doi":"10.20471/lo.2023.51.01.02","DOIUrl":"https://doi.org/10.20471/lo.2023.51.01.02","url":null,"abstract":"Aim: To investigate the clinical and pathohistological tumor characteristics, treatment, and treatment outcomes in patients with hereditary breast and ovarian cancer who were diagnosed, treated, and monitored at the University Hospital of Split from October 1999 to April 2021. Methods: The data were collected retrospectively from the medical history of 15 patients. They included the patient’s age at diagnosis, family history of malignancies, histological subtype, grade, breast cancer immunophenotype, stage of disease, status and types of BRCA mutations, type of surgical and oncological treatment, the specifics of metachronous bilateral breast cancers, the specifics of synchronous breast and ovarian cancers, and the outcome of treatment through overall survival (OS). Results: The median age of patients at the time of diagnosis of breast cancer was 53 years, and for ovarian cancer it was 56 years. A positive family history was confirmed in 13 patients (87%). All ovarian cancer patients had a high-grade serous histologic type, most often diagnosed in FIGO stages III and IV. Breast cancers were most commonly diagnosed in stages IA and IIA, with equally represented triple-negative and luminal immunophenotypes. The most common mutation was BRCA1 c.5266dup. The median OS of our patients was not reached. Conclusion: The clinical features of patients, pathohistological characteristics of tumors, and treatment outcomes in our study population are comparable with reports in the literature, respecting the specifics of different nations and race","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46427802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.23
Mirela Šambić-Penc, Luka Perić, Ivana Canjko, Maja Kovač-Barić, Darko Kotromanović, Josipa Flam
Penile cancer is a rare but aggressive tumor, most commonly squamous cell carcinoma. Treatment modalities depend on the stage of the disease, but the backbone of treatment is surgical resection of the primary tumor and regional lymph nodes with the use of neoadjuvant/adjuvant chemotherapy and radiotherapy. Our case report is about a 59-year-old patient which was presented with bilateral inguinal lymphadenitis, scrotal and penile edema. A biopsy of the change in the penis confirmed squamous cell carcinoma. Partial amputation of the penis and an excisional biopsy of the inguinal lymph nodes was performed, which confirmed the metastasis to the lymph nodes. Diagnostic imaging revealed bilateral enlarged inguinal lymph nodes which were later surgically removed. Postoperative CT scan showed three suspected lung metastases. The patient was then treated with polychemotherapy. Follow-up CT scan showed complete regression of metastatic changes in the lungs but also showed local recurrence in the area of the penile root. Radiotherapy with concomitant administration of cisplatin was conducted. Penile cancer is an aggressive disease that can be cured at an early stage if adequate treatment is applied. We highlight the importance of a multimodal and multidisciplinary approach consisting of polychemotherapy, surgical treatment, and radiotherapy.
{"title":"Role of radiotherapy in the treatment of locally advanced penile cancer","authors":"Mirela Šambić-Penc, Luka Perić, Ivana Canjko, Maja Kovač-Barić, Darko Kotromanović, Josipa Flam","doi":"10.20471/lo.2022.50.02-03.23","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.23","url":null,"abstract":"Penile cancer is a rare but aggressive tumor, most commonly squamous cell carcinoma. Treatment modalities depend on the stage of the disease, but the backbone of treatment is surgical resection of the primary tumor and regional lymph nodes with the use of neoadjuvant/adjuvant chemotherapy and radiotherapy. Our case report is about a 59-year-old patient which was presented with bilateral inguinal lymphadenitis, scrotal and penile edema. A biopsy of the change in the penis confirmed squamous cell carcinoma. Partial amputation of the penis and an excisional biopsy of the inguinal lymph nodes was performed, which confirmed the metastasis to the lymph nodes. Diagnostic imaging revealed bilateral enlarged inguinal lymph nodes which were later surgically removed. Postoperative CT scan showed three suspected lung metastases. The patient was then treated with polychemotherapy. Follow-up CT scan showed complete regression of metastatic changes in the lungs but also showed local recurrence in the area of the penile root. Radiotherapy with concomitant administration of cisplatin was conducted. Penile cancer is an aggressive disease that can be cured at an early stage if adequate treatment is applied. We highlight the importance of a multimodal and multidisciplinary approach consisting of polychemotherapy, surgical treatment, and radiotherapy.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47654631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.13
Ozana Miličević, Ines Trkulja, Andrija Matijević, Loris Ćurt, Patricija Sesar, Meliha Solak, S. Ramić, I. Kirac
Background: The prognosis of rectal cancer has improved with neoadjuvant treatment for locally advanced disease. Twenty percent of patients respond to treatment with complete pathological regression, which is clinically estimated with magnetic resonance imaging. Aim: describe the properties of the pathological complete response group of patients at our institution Materials and methods: All selected patients received LCCRT at the University Hospital for Tumors Sestre milosrdnice University Hospital Center, Zagreb, between January 2014 and December 2019 and were later surgically treated at the same facility. Results: We identified 23 patients with complete pathological responses, of which, despite surgery, seven progressed. We recorded a higher proportion of female patients in that group and younger age of onset. MRI preoperatively was not yet predictive of a complete pathological response. Conclusion: The proportion of patients with a complete pathological response is 16% in this cohort. All patients underwent surgery but did not receive consolidating therapy. About 30% progressed during the observed period.
{"title":"Complete pathological response following neoadjuvant chemoradiotherapy in locally advanced colorectal carcinoma","authors":"Ozana Miličević, Ines Trkulja, Andrija Matijević, Loris Ćurt, Patricija Sesar, Meliha Solak, S. Ramić, I. Kirac","doi":"10.20471/lo.2022.50.02-03.13","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.13","url":null,"abstract":"Background: The prognosis of rectal cancer has improved with neoadjuvant treatment for locally advanced disease. Twenty percent of patients respond to treatment with complete pathological regression, which is clinically estimated with magnetic resonance imaging. Aim: describe the properties of the pathological complete response group of patients at our institution Materials and methods: All selected patients received LCCRT at the University Hospital for Tumors Sestre milosrdnice University Hospital Center, Zagreb, between January 2014 and December 2019 and were later surgically treated at the same facility. Results: We identified 23 patients with complete pathological responses, of which, despite surgery, seven progressed. We recorded a higher proportion of female patients in that group and younger age of onset. MRI preoperatively was not yet predictive of a complete pathological response. Conclusion: The proportion of patients with a complete pathological response is 16% in this cohort. All patients underwent surgery but did not receive consolidating therapy. About 30% progressed during the observed period.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44022873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.12
Karmela Ana Popović, L. Mayer, I. Milas, Mihaela Gaće, Milica Šoštarić, M. Šekerija, Franjo Stručić, D. Verbanac
Breast cancer is the most common malignant disease among women, constituting around a quarter of all cancers in women worldwide. This type of cancer is mainly affected by genetic, environmental, and lifestyle factors such as nutrition and physical activity. A retrospective study including 192 women with breast cancer was performed for six years (from 2015 to 2021). We investigated the relationship between indirect hematological parameters, neutrophil-to lymphocyte ratio – NLR, plateletsto-lymphocyte ratio – PLR, systemic immune-inflammation index – SII and the treatment outcome. Additionally, we also followed the overall survival (OS) rate. The obtained results report assessed parameters before and after surgical intervention. Of importance is to emphasize that at a cut-off value of 2.65 (P = 0.001) and 3.30 (P < 0.001), a decline in the NLR value was noticed after surgical removal of the breast cancer. The same decrease was observed for SII after surgery (P < 0.001). Through the study, SII has been shown to be a more relevant parameter compared to NLR and PLR. The study outcome recommends the cut-off value of 2.65 as the optimal for NLR in predicting the effectiveness and successfulness of the surgical procedure.
{"title":"Prognostic significance of preoperative computed hematological inflammatory parameters in patients with breast cancer","authors":"Karmela Ana Popović, L. Mayer, I. Milas, Mihaela Gaće, Milica Šoštarić, M. Šekerija, Franjo Stručić, D. Verbanac","doi":"10.20471/lo.2022.50.02-03.12","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.12","url":null,"abstract":"Breast cancer is the most common malignant disease among women, constituting around a quarter of all cancers in women worldwide. This type of cancer is mainly affected by genetic, environmental, and lifestyle factors such as nutrition and physical activity. A retrospective study including 192 women with breast cancer was performed for six years (from 2015 to 2021). We investigated the relationship between indirect hematological parameters, neutrophil-to lymphocyte ratio – NLR, plateletsto-lymphocyte ratio – PLR, systemic immune-inflammation index – SII and the treatment outcome. Additionally, we also followed the overall survival (OS) rate. The obtained results report assessed parameters before and after surgical intervention. Of importance is to emphasize that at a cut-off value of 2.65 (P = 0.001) and 3.30 (P < 0.001), a decline in the NLR value was noticed after surgical removal of the breast cancer. The same decrease was observed for SII after surgery (P < 0.001). Through the study, SII has been shown to be a more relevant parameter compared to NLR and PLR. The study outcome recommends the cut-off value of 2.65 as the optimal for NLR in predicting the effectiveness and successfulness of the surgical procedure.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41535687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.22
Helga Sertić-Milić, Nikolina Jurjević, Thomas Ferenc, Jelena Svetec-Dvorski, Mirta Zekan-Vučetić, V. Vidjak
A hepatocellular carcinoma (HCC) is a primary liver malignancy, often arising in the setting of chronic liver disease. Incidence of this carcinoma is increasing at a great rate. Disease often manifests asymptomatically and to make the final diagnosis is often challenging. Screening of patients at risk is based on ultrasound (US) examinations, which in the setting of suspicion lesion findings often converts to multiphasic computed tomography (CT) and magnetic resonance imaging (MRI) procedures for advanced disease evaluation. The selection of treatment modality depends on tumor size and location, extrahepatic spread and subsequent liver disease. For years the first line of treatment was liver resection and transplantation. Locoregional therapy is a novel approach to diverse stages of HCC with good response and higher overall survival rates, especially in early stages. Transarterial chemoembolization (TACE) is the method of choice in patients with multifocal HCC and maintained liver function, unsuitable for surgical treatment. We present a patient with HCC in the setting of hepatitis C virus (HCV) infection, treated with combined methods of locoregional therapy.
{"title":"Locoregional treatment approaches for hepatocellular carcinoma – a case report","authors":"Helga Sertić-Milić, Nikolina Jurjević, Thomas Ferenc, Jelena Svetec-Dvorski, Mirta Zekan-Vučetić, V. Vidjak","doi":"10.20471/lo.2022.50.02-03.22","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.22","url":null,"abstract":"A hepatocellular carcinoma (HCC) is a primary liver malignancy, often arising in the setting of chronic liver disease. Incidence of this carcinoma is increasing at a great rate. Disease often manifests asymptomatically and to make the final diagnosis is often challenging. Screening of patients at risk is based on ultrasound (US) examinations, which in the setting of suspicion lesion findings often converts to multiphasic computed tomography (CT) and magnetic resonance imaging (MRI) procedures for advanced disease evaluation. The selection of treatment modality depends on tumor size and location, extrahepatic spread and subsequent liver disease. For years the first line of treatment was liver resection and transplantation. Locoregional therapy is a novel approach to diverse stages of HCC with good response and higher overall survival rates, especially in early stages. Transarterial chemoembolization (TACE) is the method of choice in patients with multifocal HCC and maintained liver function, unsuitable for surgical treatment. We present a patient with HCC in the setting of hepatitis C virus (HCV) infection, treated with combined methods of locoregional therapy.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43624450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：